Key Stats for Charles River Stock
- Post-Earnings Move: +3.95%
- Current Price: $168.92
- Valuation Model Target: $218.84
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>
What Happened?
Charles River Laboratories (CRL) shares held relatively steady this week, edging up 3.95% following their earnings report.
The modest bump came after CRL reported a solid Q4 earnings beat that signaled a stabilization in the broader preclinical research market.
The company generated $994.2 million in revenue, edging past Wall Street expectations.
Additionally, Adjusted EPS came in at $2.39, beating the consensus estimate of $2.35.
The underlying narrative for CRL is closely tied to the recent resurgence in biotechnology funding.
After a brutal funding drought that forced many small and mid-sized biotech firms to pause their research pipelines, capital is finally flowing back into the sector.
Management noted that biotech funding hit a record $28 billion in the fourth quarter, which directly translated to a stronger “book-to-bill” ratio for Charles River’s crucial Discovery and Safety Assessment (DSA) segment.
Despite the improving macro environment, CRL stock remains heavily discounted due to fears that Artificial Intelligence will disrupt animal testing.
Wall Street is concerned that “New Approach Methodologies” (NAMs), such as AI models and virtual control groups, will eventually replace the need for the physical research models that CRL provides.
See analysts’ growth forecasts and price targets for Charles River stock (It’s free!) >>>
Is Charles River Undervalued Today?
The TIKR Model indicates that the market is severely overestimating the speed of AI disruption in the highly regulated FDA safety assessment space.
The model projects a target price of $218.84, representing a solid +29.6% upside from current levels.
During the earnings call, CEO Jim Foster directly addressed the AI panic that has weighed on the stock.
He explained that while AI is a useful tool for early discovery, it is nowhere close to replacing physical safety testing.
Foster stated verbatim: “NAMs, including AI, has promise, but it still has challenges with data availability and proof of concept, so it will be a gradual longer-term evolution led by science and the validation of new capabilities over time, particularly in the regulated safety assessment environment where patient safety is paramount.”
Furthermore, the company has aggressively moved to secure its supply chain for Non Human Primates (NHPs), which remain essential for drug approval.
Foster highlighted their recent acquisitions to protect this moat, stating: “Between K.F. and Noveprim, we expect to own and internally source most of our future annual NHP supply requirements for the DSA segment.”
Read the full Charles River Transcript on TIKR to see the biotech funding breakdown >>>
Valuation Deep Dive
The TIKR Advanced Valuation Model identifies Charles River as a highly resilient, essential service provider that is currently mispriced due to long-term technology fears.
- Target Price: $218.84
- Current Price: $168.92
- Annualized Return: 5.5%
The Supply Chain Moat: A major headwind for CRL over the last two years has been the volatile cost and availability of NHPs. By acquiring their Cambodian supplier (K.F.), CRL has effectively locked down its supply chain. Management expects this acquisition to generate significant cost savings and improve operating margins by more than 100 basis points in the DSA segment starting in the second half of 2026.
Steady Margin Protection: While revenue growth has been muted during the biotech funding drought, CRL has successfully protected its profitability. The company expects to generate at least $100 million in incremental cost savings in 2026. As biotech funding converts into actual study starts later this year, the combination of lower sourcing costs and a leaner operational structure should drive significant earnings leverage.
Conclusion: A wide moat business temporarily discounted by AI hype. With a projected +29.6% total return potential, Charles River offers a compelling entry point for investors who understand the slow-moving reality of FDA regulations. The path to $218 is supported by recovering biotech capital, a secured NHP supply chain, and steady margin expansion.
See what stocks billionaire investors are buying so you can follow the smart money with TIKR.
How Much Upside Does Charles River Stock Have From Here?
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
